Exciting News for Theratechnologies Inc. Theratechnologies Inc. Submits Prior Approval Supplement to FDA MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has recently announced a significant milestone in its journey. The Company has submitted a Prior Approval Supplement…

Dynacor Group Inc. Reports Decrease in Gold Sales for November 2024 Overview Dynacor Group Inc. (TSX-DNG), an international gold ore industrial corporation that caters to ASMs (artisanal and small-scale miners), recently announced a decrease in their unaudited gold sales for November 2024. The corporation recorded sales of US$16.6 million (C$23.2 million) for the month, down…

Endeavour Announces Transaction in Own Shares London, 18 December 2024 – Endeavour Mining plc (LSE:EDV, TSX:EDV) Transaction Details: The Company has purchased 42,000 of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited. The dates of purchase were 17 December 2024. The lowest price paid per share was 1,425.00 GBp, while the…

Feeling Like a Superhero: Imlifidase, the New Breakthrough in GBS Treatment By: Your Quirky Pharmacist Friend Hey there, fellow health warriors! Ready to dive into the latest news in medical breakthroughs that are changing the game? Well, buckle up because today we’re talking about Hansa Biopharma’s exciting announcement about imlifidase and its positive results in…

Transaction in Own Shares 17 December, 2024 Shell plc Announces Purchase of Shares Shell plc (the ‘Company’) has recently announced that on 17 December 2024, it purchased a significant number of shares for cancellation. The aggregated information on the shares purchased reveals interesting data about the trading venues and prices involved in these transactions. Let’s…

Xenetic Biosciences Extends Research Agreement with University of Virginia for DNase-Based Oncology Platform Dr. Reid Bissonnette Discusses the Advancement of Innovative Immune-Oncology Technologies In a recent Virtual Investor segment, Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic Biosciences, discussed the company’s extended Research Agreement with the University of Virginia for the…